KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Current Assets (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Current Assets data on record, last reported at $662.5 million in Q4 2025.

  • For Q4 2025, Current Assets rose 10.66% year-over-year to $662.5 million; the TTM value through Dec 2025 reached $662.5 million, up 10.66%, while the annual FY2025 figure was $662.5 million, 10.66% up from the prior year.
  • Current Assets reached $662.5 million in Q4 2025 per EBS's latest filing, down from $786.9 million in the prior quarter.
  • Across five years, Current Assets topped out at $1.3 billion in Q4 2021 and bottomed at $598.7 million in Q4 2024.
  • Average Current Assets over 5 years is $922.9 million, with a median of $935.6 million recorded in 2022.
  • Peak YoY movement for Current Assets: skyrocketed 88.49% in 2021, then crashed 44.13% in 2024.
  • A 5-year view of Current Assets shows it stood at $1.3 billion in 2021, then dropped by 4.69% to $1.2 billion in 2022, then plummeted by 43.86% to $679.5 million in 2023, then dropped by 11.89% to $598.7 million in 2024, then increased by 10.66% to $662.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $662.5 million in Q4 2025, $786.9 million in Q3 2025, and $719.5 million in Q2 2025.